Stealth BioTherapeutics (Stealth BioTherapeutics) Net Income From Continuing Operations : $-52.97 Mil (TTM As of Mar. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Stealth BioTherapeutics Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Stealth BioTherapeutics's net income from continuing operations for the three months ended in Mar. 2022 was $-8.14 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2022 was $-52.97 Mil.

Stealth BioTherapeutics Net Income From Continuing Operations Historical Data

The historical data trend for Stealth BioTherapeutics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stealth BioTherapeutics Net Income From Continuing Operations Chart

Stealth BioTherapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Income From Continuing Operations

Get a 7-Day Free Trial

-82.91

-96.71

-71.73

-57.46

-52.53

Stealth BioTherapeutics Quarterly Data
	Dec16	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Net Income From Continuing Operations	Get a 7-Day Free Trial															-7.69	-18.41	-6.30	-20.14	-8.14

Stealth BioTherapeutics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-52.97 Mil.

Stealth BioTherapeutics (Stealth BioTherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stealth BioTherapeutics Corp (NAS:MITO) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Intertrust Corporate Services (Cayman) Limited, One Nexus way, Camana Bay, Grand Cayman, CYM, KY1-9005

Website

https://www.stealthbt.com

Stealth BioTherapeutics Corp is a clinical-stage biotechnology company. It is focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction.